Please assess the completion status of the following clinical trial:

Trial Title: Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Metastatic castration-resistant prostate cancer (CRPC)~* Previous anti-androgen therapy and progression after withdrawal~* ECOG performance status of either 0 or 1~* Medical or surgical castration with testosterone less than 50 ng/dL~* Life expectancy of at least 6 months~Exclusion Criteria:~* Prior cytotoxic chemotherapy or biologic therapy for CRPC~* Prior ketoconazole for prostate cancer~* Known brain metastasis or visceral organ metastasis~* Use of opiate analgesics for cancer-related pain, including codeine and dextropropoxyphene, currently or anytime within 4 weeks of Cycle 1 Day 1

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo + prednisone (Type: PLACEBO_COMPARATOR): Placebo plus prednisone
- Abiraterone + prednisone (Type: EXPERIMENTAL): Abiraterone acetate plus prednisone

Based on this trial design, predict the completion outcome and termination type (if applicable).